Brodalumab and Parsabiv - Can't get approved When they get approved, Amgen can't sell them (Repatha, Corlanor) Is this company a joke or what? The glory days are long gone.
Don't forgot Kyprolis hasn't reached $1B dollars 4 years post launch. This product was worth only a $4B acquisition cost. Amgen overspends again.